Teva launches authorized generics: Actos, ACTOplus met
Teva Pharmaceutical Industries Ltd has launched authorized generics of products indicated for use with diet and exercise to improve blood glucose control in adults with type 2 diabetes.
Teva Pharmaceutical Industries Ltd has launched an authorized generic (AG) of Actos (pioglitazone hydrochloride tablets) in 15-mg, 30-mg, and 45-mg dose strengths, as well as an AG of ACTOplus met (pioglitazone/metformin tablets) in 15 mg/500 mg and 15 mg/850 mg dose strengths. Both products are indicated for use with diet and exercise to improve blood glucose control in adults with type 2 diabetes.
Actos and ACTOplus met are marketed by Takeda Pharmaceuticals U.S.A.
The brand product, Actos, had annual sales of approximately $2.7 billion in the United States, and the combination product, ACTOplus met, had annual sales totaling $413 million in the United States, according to IMS sales data as of June 30, 2012.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
